Fig. 6.

PTP1B pharmacological inhibition attenuates ethanol-induced hepatic injury, inflammation, steatosis, and oxidative stress. A) Schematic depicting the administration of PTP1B inhibitor (PTP1Bi; DPM-1001) in the chronic plus binge model. Wild-type female mice were provided 5% EtOH liquid diet without (white arrow) and with PTP1B inhibitor (black arrow) for ten days. Mice were sacrificed 9 h post oral gavage of 31.5% EtOH (0.02 ml/g body weight) on day 11. (B) Plasma ALT level (left panel; n = 6 EtOH and n = 7 EtOH + PTP1Bi) and hepatic mRNA of Il1b, Ccl2 and Tnfa (right panel; n = 4 per group), and (C) hepatic triglycerides (TGs; n = 7 EtOH and n = 8 EtOH + PTP1Bi) and mRNA of Fasn, Pparg and Srebf1 (right panel; n = 4 each group) are presented as means + SEM. *p < 0.05, **p < 0.01 EtOH vs. EtOH + PTP1Bi by a two-tailed t-test. D) Immunoblots of pNF-κB, NF-κB, pAKT, AKT, pERK, ERK, NOX2, NOX4, SOD1, GPx1/2, and GAPDH in mouse liver lysates. Each lane represents an independent animal.